|
|
Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary AML Subtypes: Modeling Best Practices for Early Identification and Individualized Care
Are you optimally treating secondary AML subtypes per latest evidence on selection of therapies? To optimize treatment, clinicians must not only have current knowledge of the up-to-date classification and risk stratification strategies, but the operational frameworks to effectively translate this latest evidence into treatment selection practices. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensu... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|